Analyst Reco. Bolt Biotherapeutics, Inc.

Equities

BOLT

US0977022039

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 16/04/2026 BST			5-day change	1st Jan Change
4.810 ^USD	-2.04%		+6.65%	-12.03%

03-12	Bolt Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-11	Bolt Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI

Analyst Reco.

15/05/24	Leerink Partners Downgrades Bolt Biotherapeutics to Market Perform From Outperform, Adjusts PT to $1 From $3	MT
15/05/24	Guggenheim Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/05/24	HC Wainwright Downgrades Bolt Biotherapeutics to Neutral From Buy	MT
15/05/24	Stifel Downgrades Bolt Biotherapeutics to Hold From Buy, Adjusts Price Target to $1.50 From $6	MT
12/05/23	SVB Securities Upgrades Bolt Biotherapeutics to Outperform From Market Perform, Price Target is $4	MT
24/01/23	Morgan Stanley Cuts Price Target on Bolt Biotherapeutics to $3 From $5, Maintains Equal-Weight Rating	MT
04/10/22	HC Wainwright Starts Bolt Biotherapeutics at Buy With $8 Price Target	MT
11/08/22	Stifel Nicolaus Lowers Price Target for Bolt Biotherapeutics to $7 From $13, Maintains Buy Rating	MT
11/08/22	SVB Securities Downgrades Bolt Biotherapeutics to Market Perform from Outperform, Adjusts Price Target to $4 from $8	MT
17/05/22	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $5 from $7, Keeps Equalweight Rating	MT
16/05/22	Stifel Adjusts Bolt Biotherapeutics' Price Target to $13 From $16, Reiterates Buy Rating	MT
01/02/22	Morgan Stanley Adjusts Bolt Biotherapeutics' Price Target to $7 from $11, Keeps Equalweight Rating	MT
06/01/22	Morgan Stanley Downgrades Bolt Biotherapeutics to Equalweight from Overweight, Adjusts Price Target to $11 from $45	MT
07/12/21	Stifel Adjusts Bolt Biotherapeutics' Price Target to $19 From $34, Reiterates Buy Rating	MT
10/11/21	SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $33 from $35, Keeps Outperform Rating	MT
16/08/21	BOLT BIOTHERAPEUTICS : SVB Leerink Raises Bolt Biotherapeutics' Price Target to $35 From $34, Maintains Outperform Rating	MT
06/04/21	BOLT BIOTHERAPEUTICS : SVB Leerink Adjusts Price Target on Bolt Biotherapeutics to $37 From $36, Maintains Outperform Rating	MT
02/03/21	BOLT BIOTHERAPEUTICS : Morgan Stanley Starts Bolt Biotherapeutics at Overweight With $45 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : SVB Leerink Starts Bolt Biotherapeutics at Outperform With $36 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : Stifel Starts Bolt Biotherapeutics at Buy With $40 Price Target	MT
02/03/21	BOLT BIOTHERAPEUTICS : Guggenheim Starts Bolt Biotherapeutics at Buy With $42 Price Target	MT